MEXICO CITY, July 29 /PRNewswire-FirstCall/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma" or "the Company"), a leading Mexican over-the-counter pharmaceuticals and personal care products company announced yesterday that it had acquired the brand and related rights and registrations of UNIGASTROZOL, from Unipharm de Mexico, S.A. de C.V. This over-the-counter product is used for the reduction and control of gastrointestinal symptoms that are produced by excessive acid secretion and is also helpful in the treatment of gastritis, heartburn, reflux and esophagitis. It is based on a molecule that allows for faster absorption than that of Omeoprazol.
With this acquisition, Genomma Lab complements its line of anti-acid products, in particular its product Genoprazol. The category under which Unigastrozol participates reached sales of over US$ 50 million in 2007.
This is Genomma's first acquisition since listing on the Mexican Stock Exchange in June, when it raised capital seeking to accelerate growth.
Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing over-the-counter pharmaceutical and personal care products companies in Mexico and has a growing international presence. Genomma develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has significantly grown its revenue and profitability through a combination of a successful new product development process, consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model.
Genomma's shares are listed on the Mexican Stock Exchange under the ticker symbol "LAB".
Web Site: http://www.genommalab.com
Contact in Mexico City: Kristi King Etchberger, CFO;
email@example.com; Tel. (55) 5081 0
|SOURCE Genomma Lab Internacional, S.A.B. de C.V.|
Copyright©2008 PR Newswire.
All rights reserved